NCT02221401View on ClinicalTrials.gov

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2010

Conditions
Healthy
Interventions
DRUG

Linagliptin/Metformin FDC

DRUG

Linagliptin

DRUG

Metformin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02221401 - Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers | Biotech Hunter | Biotech Hunter